CombiGene has published its interim report for the second quarter and substantial emphasis is on the

CombiGene has entered into a new license agreement with Spark Therapeutics regarding intellectual property related to the

CombiGene’s former Director Preclinical Development Annika Ericsson has taken over the role of the company’s Chief

CombiGene is moving towards the toxicological studies in the COZY01 pain project, which is being conducted

Orphazyme has acquired 10 per cent of the shares in CombiGene, making the Danish investment company

CombiGene has terminated the preclinical development of the lipodystrophy project CGT2 after the data did not

CombiGene has regained the global rights to the epilepsy project CG01 from Spark Therapeutics after the

CombiGene, together with its Danish partner Zyneyro, has received welcome financial support of 8,6 million SEK

In CombiGene’s Q3 report, the terminated agreement with Spark Therapeutics takes up considerable space, for obvious

CombiGene has chosen Charles River Laboratories as a partner for the peptide-based pain project COZY01, which